Evidence, Access & Pricing

Value

We support our clients to develop and communicate a clear value strategy that is supported by compelling evidence.

Providing the right evidence to payers and other key access stakeholders is essential to unlock the pricing and access potential of therapies (new and on-market). Working across the product lifecycle, and by leveraging our deep and long-standing experience with payers and other stakeholders, Trinity experts can help clients to: 

  • Identify the most impactful target value story for your therapy 
  • Determine the key evidence gaps that need to be prioritized 
  • Design an evidence-generation roadmap and studies to address these gaps  
  • Develop compelling materials to educate access stakeholders pre-launch and post-launch  
  • Present the value story and supporting evidence to justify price decisions 
  • Support the development of AMCP and global value dossiers, as well as their local adaptations
  • Payer Value Proposition

    Our experts have a deep understanding of the payer audience and how to impactfully communicate the key points of a value proposition in a compelling way that is targeted and refined to audience.

    The Trinity Difference:

    • We understand the priorities of different payer types that impact their decision-making, and deliver tailored value messages to meet their specific priorities and needs
    • Our payer value propositions present a clear, concise story that builds upon itself
    • Our extensive payer network can be leveraged to pressure-test and refine the value story
    • We develop reactive messaging to mitigate payer concerns in an Objection Handler
    • We develop global tools and can provide regionally specific adaptations (e.g., Payer Information Exchange [PIE] in the U.S.)

Latest Evidence, Value, Access and Pricing Intelligence 

Dawn of a New Era: Evolving Needs, Solutions and Technology in U.S. HEOR

Dawn of a New Era: Evolving Needs, Solutions and Technology in U.S. HEOR

The U.S. health economics and outcomes research (HEOR) field has seen many changes over the last decade, including significant growth driven by payers, regulators and clinicians who are increasingly looking to Real-World Evidence (RWE) as a valuable source for patient-level data. […]

Read now

HTA/Reimbursement Evolution and Priorities for Assessment in a Value-Based Healthcare Environment in Latin America

HTA/Reimbursement Evolution and Priorities for Assessment in a Value-Based Healthcare Environment in Latin America

This session will discuss trends in the HTA/Reimbursement environment in Latin America and the drivers for value-based health care (VBHC) implementation within the region. The potential benefits of VBHC […]

Watch now

France Pilots Opportunity to Increase Speed to Reimbursement for Select Innovative Products

France Pilots Opportunity to Increase Speed to Reimbursement for Select Innovative Products

French president Emmanuel Macron announced a two-year trial that will allow pharmaceutical products that receive an ‘Amélioration du Service Médical Rendu’ (ASMR) rating of IV or better to get reimbursement […]

Read now

The Humira Case: Exploring the Blockbuster Ahead of United States Biosimilar Launch

The Humira Case: Exploring the Blockbuster Ahead of United States Biosimilar Launch

Up to nine biosimilar versions of Humira (adalimumab) are expected to launch in 2023 in the United States, following settlements between AbbVie and their respective manufacturers. In contrast, biosimilar versions of adalimumab have been available in most countries […]

Read now

Meet Our Value Experts 

Monica Martin de Bustamante

Monica Martin de Bustamante

Senior Partner &
Head of Advisory and Evidence, Value, Access and Pricing (EVAP)

Monica’s career has focused on pharmaceutical global pricing and market access issues for biopharmaceutical and pharmaceutical products. Her time has been apportioned between the mature and emerging markets, with deep expertise in the U.S., EU5, CAN and JPN. Monica has worked across the major therapeutic areas (oncology, cardiovascular, neurology, metabolic, autoimmune, gastrointestinal, respiratory, etc.) collaborating […]

Meet the Team

Robert Albarano

Robert Albarano

Managing Director

Rob is a Managing Director in Trinity’s Evidence, Value, Access and Pricing practice. Prior to joining Trinity, Rob was a Managing Director (Partner) at L.E.K. Consulting. Rob has 20+ years of healthcare strategy consulting experience, including ~15 years of Market Access and commercial strategy experience. His Market Access experience includes developing launch, pricing, innovative and […]

Meet the Team

Valeria Boers Trilles

Valeria Boers Trilles

Director,
Value, Access & Pricing

Ms. Boers is a Director in Trinity’s Value, Access & Pricing practice. Prior to joining Trinity, Ms. Boers was part of the CBPartners team and focused her experience on pricing and market access engagements, proving strategic support to optimize value communication, product positioning, IRP-based launch sequence and pricing opportunity across a range of therapeutic areas, […]

Meet the Team

Christian Frois

Christian Frois

Partner,
Value, Access & Pricing

Christian is a recognized and widely published expert on pricing, contracting, market access and payer evidence strategy. He leads Trinity’s pricing, market access, reimbursement and contracting (PARC) group, and has supported the development of PARC strategies for more than 50 assets in the US and ex-US.

Meet the Team

Andrew Gould

Andrew Gould

Partner,
Value, Access & Pricing

Mr. Gould is a Managing Director in Trinity’s Value, Access, and Pricing practice. Prior to joining Trinity, he led CBPartners’ U.S. Center of Excellence and focused on managed markets strategy engagements. His experience has emphasized the development of numerous pricing and access strategies for both pre-launch and in-line assets within the U.S. Specifically, Mr. Gould […]

Meet the Team

John Greenaway

John Greenaway

Partner,
Value, Access & Pricing

John has 25 years of consulting experience and is currently a leadership team member within Trinity’s Evidence, Value, Access and Pricing (EVAP) practice. John is an expert in U.S. Reimbursement and Contracting where he focuses on Market Access Strategy through Managed Care and Provider / GPO Contract Strategies and sustainable contract structure and design. In […]

Meet the Team

Nandini Hadker

Nandini Hadker

Partner,
Evidence Strategy

An economist by training, Nandini is a Partner at Trinity Life Sciences with over two decades of experience in custom research and strategy consulting. She is seasoned at helping clients identify what evidence will be crucial in driving their product’s success, generating that evidence using publication-grade research, and pulling the insights through scientific dissemination. She […]

Meet the Team

Maximilian Hunt

Maximilian Hunt

Partner,
Value, Access & Pricing

Max is a Partner in Trinity’s Value, Access and Pricing practice. His experience as a global life sciences strategy consultant spans all stages of product development and a wide range of therapeutic areas, including oncology, inflammatory conditions, rare diseases and cell and gene therapies.   Prior to joining Trinity, Max’s engagement work at CBPartners targeted a […]

Meet the Team

Miguel Martín de Bustamante

Miguel Martín de Bustamante

Partner,
Value, Access & Pricing

Prior to joining Trinity, Mr. Martín de Bustamante worked across CBPartners’s practices, with a focus on Value, Access, and Pricing. He developed expertise across many related areas, including innovative contracting and access models, strategic product / portfolio positioning, IRP and commercial opportunity based launch sequencing, as well as value positioning across various therapeutic areas. He […]

Meet the Team

Matt O'Hara

Matt O’Hara

Partner,
Evidence Strategy

Matt joins Trinity with over 20 years of life sciences consulting experience. During his career, Matt has worked with both pharmaceutical and medical device clients across business/commercial strategy (pricing, market access, product portfolio rationalization, acquisitions, Intellectual Property, and market insights), HEOR (value proposition development, evidence generation planning, and literature reviews, budget impact and comparative effectiveness […]

Meet the Team

Bami Oshinowo

Bami Oshinowo

Partner, Value, Access & Pricing
& London Office Lead

Prior to joining Trinity, Ms. Oshinowo led engagement work within the Value, Access and Pricing Practice and drove the Early VAP & CP Centre of Excellence at CBPartners. Her primary expertise is on early-stage pipeline issues related to commercial strategy, including competitive positioning, pricing, market access and trial design optimization. Her geographical expertise includes the USA […]

Meet the Team

Shinkyu Park

Shinkyu Park

Director

Mr. Park is a Director in Trinity’s Value, Access & Pricing practice. Prior to joining Trinity, Mr. Park’s work at CBPartners was primarily focused on pricing, market access, and value demonstration engagements in support of strategic planning with a variety of biopharmaceutical clients. Mr. Park has led many global (including USA, EU, APAC and LatAm) […]

Meet the Team

Julia Pikus

Julia Pikus

Principal,
Value, Access & Pricing

Julia is a Principal in Trinity’s Value, Access & Pricing practice. Prior to joining Trinity, Julia led engagement work within the Value, Access and Pricing Practice and drove the Cell and Gene Therapy Centre of Excellence at CBPartners. In this capacity, she supported a range of qualitative and quantitative engagements to inform current and future […]

Meet the Team

If you have any questions, we’re here to answer them.
We look forward to helping identify solutions for you.